Recce Pharmaceuticals - BPOM clearance to start Phase III R327G study
Recce received approval from the Indonesian Drug and Food Regulatory Authority, Badan POM (BPOM), to start its registrational Phase III study in...
252 Views
Recce Pharmaceuticals - Topical R327G approaching pivotal stages
Recce Pharmaceuticals has made several strides in advancing its topical gel formulation (R327G) of lead anti-infective therapeutic drug candidate...
152 Views
Recce Pharmaceuticals - Taking a closer look at diabetic foot infections
We highlight the opportunity of topical RECCE® 327 (R327) to address diabetic foot infections (DFIs), which is the leading cause of limb morbidity...
200 Views
Recce Pharmaceuticals - Advances on several fronts
Recce Pharmaceuticals has reported several encouraging developments in recent weeks for its lead development compound RECCE® 327 (R327). The...
183 Views
Recce Pharmaceuticals - R&D advance (A$11.18m) extends runway
Recce Pharmaceuticals recently received A$11.18m as an R&D advance credit through an arrangement with Endpoints Capital for the R&D tax...
229 Views